Table 18:
Mean Cost ($)a | Source | ||
---|---|---|---|
First Year | Subsequent Years | ||
Health State: Diabetes-Related Complications | |||
Nephropathy | 80 | 13 | O'Brien et al 200395 |
Neuropathy | 192 | 192 | O'Brien et al 200395 |
Retinopathy | 492 | 52 | O'Brien et al 200395 |
Severe hypoglycemic event (in-patient visit) | 3,775 | 3,775 | McQueen et al, 201597 |
Cardiovascular disease | 18,682 | 4,072 | O'Reilly et al, 200796 |
Blindness | 3,483 | 2,482 | O'Reilly et al, 200796 |
Lower-extremity amputation | 43,984 | 6,024 | O'Reilly et al, 200796 |
End-stage renal disease | 28,221 | 12,808 | O'Reilly et al, 200796 |
Intervention (Trade Name) | |||
Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) | 11,811 | 11,811 | Dexcom and Animasb |
Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) | 11,534 | 11,534 | Dexcom and Animasb |
Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) | 9,211 | 9,211 | Medtronicb |
Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) | 10,097 | 10,097 | Dexcomb |
Standalone CGM plus multiple daily injections (Dexcom G5 Mobile) | 8,587 | 8,587 | Dexcomb |
SMBG plus insulin pump (Animas Vibe or MiniMed Veo) | 6,817 | 6,817 | Medtronic and Animasb |
SMBG plus multiple daily injections | 3,677 | 3,677 | Estimatec |
Abbreviations: CGM, continuous glucose monitoring; SMBG, self-monitoring of blood glucose.
We used 25% of the mean cost for calculations of standard error in our probabilistic sensitivity analysis. All costs are presented in 2017 Canadian dollars.
Manufacturer information.
See Appendix 6, Table A13, for more details.